51 citations
,
January 2024 in “Nanoscale” This review highlights recent advancements in using nanotechnology to improve the function and delivery of PROTAC drugs, despite existing challenges like low solubility and poor permeability, aiming to enhance their potential in disease treatment.
45 citations
,
July 2025 in “Journal of Medicinal Chemistry” This article discusses the development and clinical progress of PROTAC technology, particularly focusing on the New Drug Application for vepdegestrant, an estrogen receptor-targeting PROTAC, marking significant advancements in targeted protein degradation therapies.
44 citations
,
May 2023 in “MedComm” This review highlights the potential of PROTAC technology in drug discovery for previously undruggable targets, particularly in cancer therapy, while emphasizing the urgent need to discover more E3 ligase recruiters to optimize targeted protein degradation.
9 citations
,
October 2025 in “MedComm” This review discusses the development and clinical progression of PROTAC technology for targeted protein degradation, highlighting its potential to address previously "undruggable" targets but reports no new clinical results.
June 2024 in “Journal of medicinal chemistry” This study developed a method for designing peptide-based PROTAC drugs using advanced AI models, successfully identifying peptides that bind to specific receptors and incorporating them into a potential transdermal treatment for androgenetic alopecia.